Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AI-1221
- Development stage
- Preclinical
- Lead developer
- Apeximmune Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
AI-1221 is a monoclonal antibody drug candidate developed by Apeximmune Therapeutics. It is being investigated for the treatment of immune system diseases, with a primary focus on autoimmune diseases. As of May 2025, its highest development status is preclinical, and there are no reported clinical trials or approvals. The specific molecular target and mechanism of action have not been publicly disclosed[1][2].
Beyond the preview
Go deeper on AI-1221.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AI-1221.